List of Excipients in Branded Drug PATADAY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	PATADAY	olopatadine hydrochloride	0065-0272	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	PATADAY	olopatadine hydrochloride	0065-0272	EDETATE DISODIUM
Alcon Laboratories Inc	PATADAY	olopatadine hydrochloride	0065-0272	HYDROCHLORIC ACID

PATADAY Excipient Strategy and Commercial Opportunities for Olopatadine Ophthalmic Products

Last updated: August 15, 2026

Pataday is an olopatadine ophthalmic product marketed by Alcon for allergic conjunctivitis. Its commercial platform includes 0.2% once-daily, 0.7% extra-strength, and related generic olopatadine products. The current formulation uses a conventional aqueous vehicle with benzalkonium chloride, phosphate buffer, sodium chloride, purified water, and pH adjusters. The main excipient opportunity is a preservative-free or low-irritation delivery system that improves tolerability without sacrificing multidose convenience, sterility, shelf life, or manufacturing cost.

Pataday’s active ingredient is exposed to generic competition, while formulation, container-closure, dosing convenience, and consumer positioning provide the stronger sources of differentiation. Alcon’s highest-value development paths are preservative-free multidose delivery, improved ocular comfort, longer residence time, and packaging that supports premium pricing.

What excipients are used in Pataday ophthalmic solution?

Pataday 0.2% and Pataday 0.7% use similar excipient systems. The products are sterile aqueous ophthalmic solutions containing olopatadine hydrochloride and a conventional preservative-buffer vehicle.

Product	Active ingredient	Principal inactive ingredients	Commercial positioning
Pataday Once Daily Relief	Olopatadine HCl equivalent to 0.2% olopatadine	Benzalkonium chloride 0.01%, dibasic sodium phosphate, sodium chloride, hydrochloric acid or sodium hydroxide, purified water	Once-daily allergy relief
Pataday Extra Strength	Olopatadine HCl equivalent to 0.7% olopatadine	Benzalkonium chloride 0.01%, dibasic sodium phosphate, sodium chloride, hydrochloric acid or sodium hydroxide, purified water	Higher-strength, once-daily OTC product
Generic olopatadine ophthalmic solution	Commonly 0.1%, 0.2%, or 0.7%	Product-specific; many use benzalkonium chloride, phosphate buffer, sodium chloride, and water	Prescription or OTC-equivalent competition

The formulation listed in the U.S. product labeling uses benzalkonium chloride, or BAK, as the antimicrobial preservative. Dibasic sodium phosphate provides buffering capacity. Sodium chloride contributes to tonicity, while hydrochloric acid and sodium hydroxide adjust pH. DailyMed identifies these ingredients for Pataday ophthalmic products and provides the corresponding FDA labeling information.[1,2]

The formulation is technically simple. That reduces manufacturing complexity but also lowers the barrier to generic substitution and makes excipient differentiation commercially important.

Why is benzalkonium chloride strategically important in Pataday?

BAK supports multidose sterility but can create tolerability concerns for patients with frequent use, ocular-surface disease, contact-lens wear, or concomitant glaucoma therapy. The principal commercial issue is cumulative exposure rather than a single administration.

BAK has been associated with ocular-surface irritation and toxicity concerns in ophthalmic literature, particularly with chronic exposure and preserved multidose products.[3] These concerns create a segmentation opportunity:

• Standard BAK-preserved product for low-cost, occasional use.
• Preservative-free product for sensitive eyes and frequent users.
• Alternative-preserved product for consumers seeking improved comfort at a lower price than unit-dose packaging.
• Premium multidose product using a preservative-free container-closure system.

The presence of BAK does not establish a product defect. It means that BAK is a potential point of differentiation for competing products and line extensions.

What excipient strategy offers the strongest commercial opportunity?

A preservative-free, multidose Pataday-equivalent product has the clearest commercial rationale. It could preserve the convenience of a bottle while addressing the principal tolerability objection to BAK.

Preservative-free multidose systems

Potential technologies include:

• One-way valve bottles that prevent microbial ingress.
• Airless pump dispensers.
• Sterile barrier systems with filtered air replacement.
• Formulations packaged in multidose containers with antimicrobial internal surfaces.
• Metered-dose systems that deliver a controlled volume per actuation.

The development target is not simply “remove BAK.” The formulation must maintain sterility throughout in-use storage, control extractables and leachables, deliver a reproducible drop, and remain compatible with olopatadine hydrochloride.

A preservative-free multidose product can support a premium price and may reduce switching barriers for patients already using preservative-free artificial tears or glaucoma medications. Its main disadvantages are higher packaging cost, more complex microbial validation, and potential device-related regulatory requirements.

Unit-dose preservative-free packaging

Unit-dose vials are technically established and offer a lower development risk than novel multidose devices. They are suitable for:

• Pediatric use.
• Travel.
• Contact-lens users.
• Patients with severe ocular-surface sensitivity.
• Short treatment courses.

The commercial limitation is inconvenience and higher packaging waste. Unit-dose packaging also increases filling, labeling, shipping, and secondary-packaging costs. It is more likely to operate as a premium niche product than as the primary Pataday platform.

Alternative preservatives

Polyquaternium-1, sodium perborate, stabilized oxychloro complex, and related systems are used in ophthalmic products, although each has a distinct toxicology, compatibility, and regulatory profile. An alternative preservative could reduce BAK-related concerns without requiring a high-cost preservative-free bottle.

This approach has a weaker marketing position than “preservative-free,” but it may offer better margins and simpler manufacturing. The product would require comparative ocular-surface tolerability data and preservative-effectiveness testing under applicable pharmacopeial standards.

Can excipients improve olopatadine solubility and ocular residence time?

Olopatadine hydrochloride is water-soluble enough for conventional aqueous ophthalmic solutions. Solubility is therefore not the primary formulation problem. The more valuable technical targets are residence time, comfort, drop size, and dosing efficiency.

Potential excipient approaches include:

• Viscosity enhancers such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, carboxymethylcellulose, or povidone.
• Mucoadhesive polymers that increase contact time on the ocular surface.
• Low-concentration hyaluronic acid or other lubricating polymers.
• Tonicity modifiers that reduce stinging.
• Buffer systems that maintain product stability while approaching physiologic pH.
• Surfactants or solubilizers, if needed for formulation robustness or container compatibility.

A viscosity increase can reduce drainage and potentially improve ocular exposure, but it can also cause blurred vision, sticky sensation, slower drop formation, or poor bottle performance. For an OTC allergy product, patient-perceived comfort may be more commercially important than a modest pharmacokinetic improvement.

The strongest formulation concept is likely a low-viscosity comfort formulation rather than a highly viscous gel. Pataday’s value proposition depends on rapid, convenient use. A product that leaves a noticeable residue may lose adherence despite longer ocular residence.

What formulations are protected by patents or regulatory exclusivity?

The active ingredient olopatadine is a mature small molecule. The commercial protection of a new product therefore depends more on formulation, dosage strength, delivery device, manufacturing process, trademark, and regulatory status than on basic composition-of-matter rights.

Potentially protectable subject matter includes:

• Specific olopatadine concentrations.
• Preservative-free aqueous formulations.
• pH and osmolality ranges.
• Polymer-containing vehicles.
• Improved drop-size or metered-dose delivery systems.
• Multidose sterile container-closure systems.
• Methods for treating allergic conjunctivitis with a selected strength or dosing schedule.
• Manufacturing processes that improve stability or sterility assurance.

Patentability would depend on claim scope, prior art, written description, enablement, and whether the claimed formulation produces an unexpected technical effect. Broad claims covering olopatadine in water, phosphate buffer, sodium chloride, and BAK would face substantial prior-art risk because those components are conventional in ophthalmic products.

A stronger patent strategy would link the excipient system to measurable performance, such as:

• Reduced ocular-surface irritation.
• Improved preservative effectiveness without BAK.
• Longer in-use sterility.
• Reduced drop volume.
• Improved dose uniformity.
• Enhanced patient comfort.
• Greater stability under temperature stress.

The Orange Book position must be evaluated product by product. FDA-listed patents, use codes, and regulatory exclusivity can differ between the 0.2% and 0.7% products and between prescription and OTC pathways. Patent listings should be checked against the current FDA Orange Book and the applicable product labeling before making a launch or litigation decision.[4]

When does Pataday lose exclusivity?

Pataday’s main commercial protections are no longer likely to be based on unexpired basic molecule exclusivity. The relevant risks are generic entry, OTC substitution, brand recognition, formulation differentiation, and potential device or formulation patents.

Protection type	Relevance to Pataday
Olopatadine composition-of-matter patent	Mature and unlikely to provide current meaningful protection
FDA prescription exclusivity	Historically relevant to initial approvals; not the main current barrier
OTC regulatory status	Supports direct consumer sale but does not prevent equivalent competition
Formulation patents	May protect specific vehicles, concentrations, or preservative systems
Device patents	May protect preservative-free multidose delivery
Trademark and brand equity	Supports pricing and shelf placement but does not block generic olopatadine
Manufacturing know-how	May create practical barriers without preventing formal market entry

Pataday 0.2% moved from prescription to OTC status in the United States in 2020. FDA approved the switch for olopatadine hydrochloride ophthalmic solution 0.2%, allowing nonprescription marketing for temporary relief of itchy and red eyes associated with allergies.[5] Pataday 0.7% is also marketed as an OTC extra-strength allergy product.

Because the products are OTC, a conventional Paragraph IV pathway is less central than it would be for a prescription product with an active Orange Book patent estate. A competitor may instead pursue an abbreviated application, an OTC monograph-based approach where available, or an NDA route depending on the product, strength, labeling, and formulation.

How do Paragraph IV challenges apply to olopatadine products?

Paragraph IV litigation is relevant when an ANDA applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The commercial relevance depends on whether the target Pataday product has listed patents and whether those patents cover the applicant’s proposed formulation or method of use.[6]

For olopatadine, the principal challenge areas are likely to be:

• Whether a listed formulation claim covers the generic vehicle.
• Whether a use code is sufficiently broad to affect the proposed label.
• Whether a 0.7% formulation is distinct from older 0.1% or 0.2% products.
• Whether the applicant can carve out a patented method of use.
• Whether a device claim applies to the proposed container-closure system.

A generic entering with a conventional BAK-preserved vehicle could avoid some device-focused claims. A preservative-free or metered-dose competitor could face a different patent profile but may also design around claims by changing polymer concentration, packaging architecture, or dosing mechanics.

What generic entry risks exist for Pataday?

Generic and private-label competition is structurally credible because olopatadine is a known small molecule and ophthalmic solution manufacturing is established. The main generic risks are:

1. Lower-priced 0.2% products replacing branded once-daily use.
2. Generic 0.7% products competing with Pataday Extra Strength.
3. Retailer-owned allergy products using the same active ingredient.
4. Switching from Pataday to other antihistamine or mast-cell stabilizer products.
5. Formulation improvements by competitors that avoid BAK or reduce irritation.

A generic does not need to replicate every brand attribute to win share. It needs adequate bioequivalence or applicable regulatory support, acceptable sterility and stability, reliable supply, and a lower price.

Pataday retains commercial advantages from brand recognition, consumer advertising, pharmacy availability, and a clear once-daily message. Those advantages are strongest in seasonal allergy markets and among consumers who select products without physician intervention.

How does Pataday compare with competing allergy eye drops?

Product class	Representative products	Typical differentiation	Excipient opportunity
Olopatadine	Pataday, generic olopatadine	Once-daily dosing; 0.2% and 0.7% strengths	Preservative-free delivery and comfort
Ketotifen	Zaditor, Alaway, generics	OTC antihistamine and mast-cell stabilizer positioning	BAK reduction, unit-dose formats
Ketorolac and other prescription agents	Prescription ophthalmic products	Different indications and tolerability profiles	Specialty formulations
Artificial tears with allergy positioning	Multiple brands	Lubrication and symptom support	Polymer systems and low-irritation packaging
Combination or emerging antihistamine products	Product-specific	Convenience or broader symptom claims	Multimodal delivery and sustained residence

Olopatadine’s once-daily dosing is a meaningful commercial asset. A new formulation should preserve that attribute. Increasing dosing frequency would weaken the product proposition unless the new product delivered a material comfort or onset advantage.

Which excipient technologies can create new commercial products?

1. Preservative-free Pataday

This is the highest-value line-extension concept. A 0.2% preservative-free product could target sensitive-eye consumers, while a 0.7% product could target patients seeking maximum once-daily strength without BAK.

2. Comfort-focused formulation

A formulation containing a lubricating polymer could combine allergy relief with reduced dryness or post-instillation discomfort. The label would need to remain within permitted claims and avoid unsupported superiority statements.

3. Premium multidose bottle

A proprietary multidose bottle could support a higher retail price and generate device patent opportunities. The device must deliver a consistent drop and remain sterile through the labeled in-use period.

4. Pediatric and travel unit doses

Unit-dose packaging could expand distribution through pediatric practices, travel retail, and specialty pharmacies. The product would likely carry higher per-dose costs but could command premium pricing.

5. International formulation platform

Different jurisdictions apply different rules to preservatives, OTC products, medical devices, and drug-device combinations. A common olopatadine formulation with region-specific packaging could reduce development duplication. Geographic expansion would require country-specific review of excipient acceptance, preservative standards, labeling, and registration pathway.

What regulatory issues affect a new Pataday formulation?

A formulation change can trigger a different regulatory pathway depending on the extent of change.

For a prescription product, a new excipient system or strength may require an NDA supplement or new application, supported by chemistry, manufacturing and controls data, stability, container-closure studies, and potentially clinical or comparative performance data.

For an OTC product, the sponsor must establish that the formulation, labeling, strength, and claims fit the applicable FDA regulatory framework. A materially different delivery system may require an NDA rather than relying on an existing monograph or an abbreviated pathway.[5,7]

Key development requirements include:

• Sterility and preservative-effectiveness testing.
• Particulate and visible-inspection controls.
• Container-closure integrity.
• Extractables and leachables evaluation.
• In-use stability.
• Drop-size and dose-delivery consistency.
• Ocular irritation and tolerability assessment.
• Photostability and temperature-stress studies.
• Compatibility with contact lenses, if claimed.
• Human factors validation for a new device.

A preservative-free product may require more extensive in-use microbial studies because the formulation cannot rely on BAK or another conventional preservative.

What is the revenue exposure from Pataday competition?

Alcon reports sales at broader Vision Care and pharmaceutical categories rather than consistently disclosing standalone Pataday revenue. Publicly available company reporting therefore does not establish a reliable product-level revenue figure.[8]

Revenue exposure is concentrated in:

• Seasonal OTC allergy demand.
• U.S. pharmacy and mass-retail distribution.
• Premium pricing for the 0.7% strength.
• Brand conversion from prescription olopatadine.
• Retailer shelf placement.
• Consumer advertising.

The most vulnerable segment is the standard 0.2% product, where a generic can offer a close therapeutic substitute. The 0.7% product may retain more differentiation if generic availability is limited, but the same active ingredient creates a long-term substitution risk.

How strong is the Pataday formulation estate?

The formulation estate is best characterized as moderate rather than intrinsically strong.

Its strengths are:

• Established commercial brand.
• Multiple strengths.
• FDA OTC recognition.
• Familiar once-daily dosing.
• Broad consumer distribution.
• Potential differentiation through packaging and line extensions.

Its weaknesses are:

• Mature active ingredient.
• Conventional aqueous excipient system.
• BAK-related switching opportunity.
• Generic manufacturing feasibility.
• Limited ability to obtain broad patents on routine excipient combinations.
• No publicly disclosed standalone Pataday revenue base sufficient to quantify brand dependence.

A stronger future estate would combine formulation claims, device claims, manufacturing know-how, trademarks, and regulatory exclusivity. A single composition patent covering conventional olopatadine solution chemistry would be less durable than a coordinated formulation-device portfolio.

Key Takeaways

• Pataday uses a conventional aqueous olopatadine formulation with BAK, phosphate buffer, sodium chloride, pH adjusters, and purified water.
• The largest excipient opportunity is a preservative-free multidose product.
• Unit-dose packaging offers a lower technical risk but has higher cost and lower convenience.
• Lubricating or mucoadhesive excipients may improve comfort and residence time, but excessive viscosity could reduce consumer acceptance.
• Olopatadine’s mature active-ingredient status shifts competitive protection toward formulation, device, manufacturing, and brand assets.
• Generic entry risk is material, especially for 0.2% olopatadine.
• Pataday 0.7% has stronger commercial differentiation but remains exposed to eventual generic substitution.
• Alcon does not consistently report standalone Pataday revenue, so product-level revenue exposure cannot be reliably quantified from public company reporting.
• The most defensible development strategy is a coordinated preservative-free formulation and proprietary multidose container-closure platform.

FAQs

Is Pataday preservative-free?

The standard Pataday 0.2% and 0.7% ophthalmic solutions listed in U.S. labeling contain benzalkonium chloride 0.01% as a preservative.[1,2]

Can a preservative-free olopatadine product compete with Pataday?

Yes. A preservative-free product could target patients with ocular-surface sensitivity, frequent eye-drop use, contact-lens use, or a preference for premium formulations. Its success would depend on packaging cost, sterility performance, comfort, and retail pricing.

Which excipient is most important in Pataday?

Benzalkonium chloride is the most commercially significant excipient because it enables multidose preservation but creates a potential tolerability-based differentiation point. The phosphate buffer and sodium chloride are important for pH and tonicity but are less commercially distinctive.

Does Pataday have biologic or biosimilar competition?

No. Pataday contains olopatadine hydrochloride, a small-molecule active ingredient. Biosimilar regulations do not apply. Competition comes from generic olopatadine products and other antihistamine or mast-cell stabilizer eye drops.

What is the most attractive patent strategy for a new olopatadine product?

The strongest strategy would combine claims covering a preservative-free or low-irritation formulation with claims covering a multidose sterile delivery device, dose uniformity, in-use sterility, and measurable comfort or stability advantages.

References

1. National Library of Medicine. (n.d.). DailyMed: Pataday ophthalmic solution, 0.2% olopatadine hydrochloride. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. National Library of Medicine. (n.d.). DailyMed: Pataday ophthalmic solution, 0.7% olopatadine hydrochloride. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. Baudouin, C., Labbe, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334. https://doi.org/10.1016/j.preteyeres.2010.03.001

4. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

5. U.S. Food and Drug Administration. (2020). FDA approves first over-the-counter eye drop for allergic conjunctivitis. https://www.fda.gov/

6. U.S. Food and Drug Administration. (n.d.). ANDA submissions: Patent certifications and 30-month stays. https://www.fda.gov/

7. U.S. Food and Drug Administration. (n.d.). Nonprescription drug products. https://www.fda.gov/drugs/over-counter-otc-nonprescription-medicines

8. Alcon Inc. (2024). Annual report. https://investor.alcon.com/financial-information/annual-reports-and-proxy-statements/